Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI Australia ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while iShares MSCI Australia ETF trades at $30.23. Which is the better fit depends on your goals.
| ACAD | EWA | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.41 | $30.41 |
52-Week Low | $20.06 | $24.95 |
Enterprise Value | $4.19B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
